secwatch.observer — SEC 8-K summary
======================================

Issuer:     BiomX Inc. (PHGE)
CIK:        0001739174
Form:       8-K
Filed at:   2025-08-19T23:59:59+00:00
Accession:  0001213900-25-078196
Event type: regulatory
Sentiment:  negative
Materiality: 0.80
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA places clinical hold on BiomX's Phase 2b study of BX004 in CF due to nebulizer device
--------------------------------------------------------------------------------

- FDA hold pauses U.S. enrollment and screening for BX004 Phase 2b trial; no concerns about BX004 itself.
- Company submitted additional data to FDA; EU study continues as nebulizer is CE marked.
- Clinical hold triggered by third-party nebulizer device, not drug candidate BX004.
- BiomX noted risks in ability to resume U.S. enrollment and timing of hold resolution.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1739174/000121390025078196/0001213900-25-078196-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1739174/000121390025078196/ea0253854-8k_biomx.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-078196

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer